+45.6%
BMY vs MRNA
+945.0%
-899.5%
-16.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.0% | +13.1% | -9.1% | +3.7% |
| 7D | +6.0% | +20.6% | -14.7% | +5.5% |
| 30D | +9.1% | +27.1% | -18.0% | +8.5% |
| 3M | -2.6% | +353.4% | -356.0% | -7.7% |
| 6M | +13.1% | +446.3% | -433.1% | +4.7% |
| YTD | +23.0% | +776.2% | -753.1% | +6.8% |
| 1Y | +45.6% | +987.9% | -942.4% | +19.5% |
| All | +45.6% | +945.0% | -899.5% | +19.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling